On The Pen GLP-1 News

Medical

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top...

Episodes

Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War

Lilly Bets $8B on Weight Loss Future

The Next Two Weeks in GLP1 Are Huge, Here's Why

He Took Retatrutide 40mg and Proved a Point

Eli Lilly Just Revealed Something About The GLP-1 Market

SURVODUTIDE Phase 3 Data: Why Weight Loss Isn't The Whole Story

BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out!

Retatrutide Could Change Everything… But Who Actually Gets It?

Ozempic Personality With Dr Spencer Nadolsky

Foundayo GLP-1 Pill: FDA Needs More Data

GLP-1 Access State of the Union

Zepbound Dosing: What Your Doctor Didn't Explain

Wegovy Price Drop Exposes a Bigger Problem

Retatrutide Is Too Good… And That’s The Problem

MASSIVE: Compound Tirzepatide and Semaglutide Updates!

Cheap Zepbound Incoming for Medicare, But CMS Just Issued a Catch

Gray Market GLP-1 Is Booming Branded Access is Broken

NEW GLP3 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?

Wegovy vs Zepbound in 2026: New Higher Dose

Compound Tirzepatide: Time to Stock Up?